Evidence map›Paper›PMID 39055918›Full record

ArticleiScience2024

Neuromedin U receptor 1 deletion leads to impaired immunotherapy response and high malignancy in colorectal cancer.

Yulai Zhou, Xiangyang Zhang, Yan Gao, Yinghui Peng, Ping Liu, Yihong Chen, Cao Guo, Gongping Deng, Yanhong Ouyang, Yan Zhang and 5 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Yulai ZhouDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Xiangyang ZhangDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Yan GaoDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Yinghui PengDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Ping LiuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Yihong ChenDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Cao GuoNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Gongping DengDepartment of Emergency, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, China.
Yanhong OuyangDepartment of Emergency, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, China.
Yan ZhangDepartment of Oncology, Yueyang People's Hospital, Yueyang Hospital Affiliated to Hunan Normal University, Yueyang, Hunan 414000, China.
Ying HanDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Changjing CaiDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Hong ShenDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Le GaoDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Shan ZengDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) exhibits significant heterogeneity, impacting immunotherapy efficacy, particularly in immune desert subtypes. Neuromedin U receptor 1 (NMUR1) has been reported to perform a vital function in immunity and inflammation. Through comprehensive multi-omics analyses, we have systematically characterized NMUR1 across various tumors, assessing expression patterns, genetic alterations, prognostic significance, immune infiltration, and pathway associations at both the bulk sequencing and single-cell scales. Our findings demonstrate a positive correlation between NMUR1 and CD8

Indexed as

BioinformaticsCancerMicroenvironmentMolecular biologyTherapeutics

Identifiers

PMID39055918
PMCPMC11269305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.